Skip to main content

Table 3 Multivariate Cox proportional hazard models for the predictors of progression free-survival

From: Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study

Factors

Univariate PFS

 

Multivariate PFS

 
 

HR (95% CI)

P

HR (95% CI)

P

Age > 65, yes

0.51 (0.31–0.87)

0.013

0.52 (0.31–0.88)

0.014

Male, yes

1.10 (0.72–1.69)

0.66

1.02 (0.65–1.56)

0.95

Favorable prognosis, yes

1.43 (0.95–2.14)

0.084

1.41 (0.93–2.1)

0.099

Karnofsky performance status ≥90, n (%)

1.18 (0.79–1.76)

0.43

≥ 2 metastatic sites, n (%)

1.35 (0.90–2.01)

0.15

Hemoglobin, g/dL

0.98 (0.87–1.10)

0.69

Leucocytes, 109/L

1.03 (0.92–1.15)

0.59

Neutrophils, 109/L

1.03 (0.91–1.17)

0.65

Platelets, 109/L

1.00 (1.00–1.005)

0.044

Total calcium, mg/dL

1.074 (0.83–1.38)

0.58

LDH, mg/dL

0.99 (0.99–1.00)

0.28

  1. Abbreviations: PFS Progression free-survival, HR Hazard ratio, CI Confidence interval. Favorable group was classified according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC model), in which favorable risk is equivalent to no factors